



BioVendor Group partners with healthcare focused investment firm ARCHIMED

BioVendor Group changes ownership to partner with a healthcare specialist, strengthening its development and expansion capacities in the global diagnostics market.

ARCHIMED is a global investment firm specialising in the healthcare industries, with biotechnology and diagnostics being among the core investment areas. With an international presence, ARCHIMED joins forces with scientists, healthcare professionals, entrepreneurs and investors to positively impact companies operating in these sectors. In particular, ARCHIMED focuses on supporting these companies in their efforts to internationalise, increase capacity, expand product ranges and make acquisitions.

ARCHIMED invests in companies with strong potential, and their approach is always based on long-term and strategic value creation. They not only provide financial support but also share expertise and leverage their companies and MEDTalent® network to foster collective sustainable growth, ultimately improving patients' outcome.

Joining forces with ARCHIMED allows us to expand our activities, strengthen our technological foundation, and offer even higher-quality services. At the same time, we remain a team grounded in the same values, expertise, and commitment.

In a statement, **Michal Kostka**, CEO of BioVendor Group, said: „ARCHIMED is taking over the baton in a well-paced long-distance race, ensuring that our momentum continues and our journey towards growth and innovation remains strong.“



Martin Zeppetzauer, CEO of ViennaLab confirms, „ViennaLab has a long history that is full of successful developments and adaptation to changing times and environments. After the transition to a part of BioVendor Group in 2020 we are now at the start of a new era that will allow us to unlock further potential together with a highly specialised and focused investor.“



About BioVendor Group

BioVendor Group is an international group of biotechnology companies with its own research, development, production of in-vitro diagnostic (IVD) products and distribution network. Since its establishment in 1992, the original Czech company has grown into a multinational group with several global offices, its own R&D department and the established brands BioVendor LM, BioVendor R&D, TestLine, DiaSource, ViennaLab and BioVendor MDx. The unique breadth of its portfolio makes the BioVendor Group one of the major players in the global diagnostics market.

About ARCHIMED

With offices in Europe, North America and Asia, **ARCHIMED** is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÉKA Foundation.



4. 3. 2025

Contact:

Jana Držíková
Marketing Manager
drzikova@biovendor.cz
+420 702 222 646

ViennaLab Diagnostics GmbH

Gaudenzdorfer Guertel 43-45
A-1120 Vienna, Austria
+43 1 812 0156
info@viennalab.com
www.viennalab.com